400
Participants
Start Date
September 20, 2023
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2026
Tirzepatide
Administered SC
Placebo
Administered SC
Rophe Adult and Pediatric Medicine/SKYCRNG, Union City
Oviedo Medical Research, Oviedo
New Horizon Research Center, Miami
Cahaba Research - Pelham, Pelham
WR-Clinsearch, LLC, Chattanooga
Prime Health and Wellness/SKYCRNG, Fayette
L-MARC Research Center, Louisville
Asha Clinical Research - Munster, Hammond
Iowa Diabetes and Endocrinology Research Center, West Des Moines
Alliance for Multispecialty Research, LLC, Norman
Southern Endocrinology Associates, Mesquite
Velocity Clinical Research, Dallas, Dallas
The University of Texas Health Science Center at Houston, Bellaire
Pinnacle Clinical Research, San Antonio
Consano Clinical Research, LLC, Shavano Park
Rocky Mountain Clinical Research, Idaho Falls
Velocity Clinical Research, Westlake, Los Angeles
Encompass Clinical Research, Spring Valley
Southern California Dermatology, Inc., Santa Ana
East-West Medical Research Institute, Honolulu
Eli Lilly and Company
INDUSTRY